Bli medlem
Bli medlem

Du är här


A1M: ROSGard™ shows renal protective effect during radiation therapy

A1M Pharma announces that the active substance in the company's
candidate drug ROSGard™ shows a strong renal protective effect in
connection with radiation therapy (PRRT) in a short-term preclinical
study with an animal model. Results of the effect 6 months after
treatment are expected by the end of Q1 2017.

During the autumn of 2016, A1M Pharma chose kidney protection in
connection with molecular targeted therapy to treat tumours (PRRT) as
their first clinical application within acute kidney injury (AKI).
PRRT is often used to treat aggressive endocrine cancer tumours in
the gastrointestinal tract and the lungs. The treatment's severe
effect on the patients' kidneys limits the maximum radiation dose
that can be used, both in separate radiation treatments and in total.

The aim is to administer the company's candidate drug ROSGard™ to
patients in connection with each radiation therapy session in order
to increase the efficacy of the treatment while protecting the

A1M Pharma has already observed a strong renal protective effect in
preclinical studies with an animal model when the active substance in
ROSGard is administered in connection with radiation therapy. So far,
the renal protective effect has been studied 1-8 days after
treatment. The results of the long-term follow up, six months after
treatment, are expected to be available by the end of Q1 2017.

"The strong renal protective effect of the active substance in
ROSGard™ in this short-term preclinical study is very encouraging,
although it is important to emphasize that we are still in early
preclinical phase. The results strengthen our conviction that kidney
protection in connection with targeted radiation therapy was a
correct choice as our first clinical application within acute kidney
injury. I am looking forward to present more conclusive results by
the end of Q1 2017 when the data six months after treatment is
expected to be available", says A1M Pharma's Head of Development
Eddie Thordarson.

In parallel with the preclinical studies, A1M is evaluating potential
partnerships with large pharmaceutical companies for the continued
development of the project. The company notices a strong interest in
the renal protective effects of the active substance in the candidate
drug ROSGard™ within the two key focus areas preeclampsia and acute
kidney injury.

For more information, please contact

Tomas Eriksson, CEO

Telephone: +46 46-286 50 30


About PRRT - molecular targeted therapy
Peptide Receptor Radionuclide Therapy, PRRT, is a type of molecular
targeted therapy used to treat tumours, commonly malignant tumours
with the generic term neuroendocrine tumours or NETs. When
aggressive, these tumours are fatal and can spread quickly to the
gastrointestinal tract and the lungs. During PRRT treatment the
patient is given a substance consisting of two parts, a tumour
targeting peptide and a radioactive substance that breaks down the
cell tissue. This powerful oxidation reaction creates waste products
that ends up in the kidneys. It is the harmful effects of these waste
products that the active substance in A1M Pharma's candidate drug
ROSGard™ is expected to eliminate and thus protect the kidneys. A
renal protective treatment enabling an increase of the maximum
radiation dose in connection with PRRT treatment, in separate
sessions and/or in total, has the potential to reach the market
relatively quickly considering the serious and fatal effects of NET
cancer tumours.

About A1M Pharma

A1M Pharma develops a diagnostic method and novel treatment for the
damaging effects of pre-eclampsia, a condition that affects around 10
million pregnant women worldwide. This disorder is responsible for
76,000 maternal and 500,000 infant deaths each year. It is also the
cause of 15 per cent of all premature births. Currently, there is no
predictive diagnostic method or treatment for impairments to kidney
function associated with pre-eclampsia. In serious cases, doctors are
forced to terminate the pregnancy which leads to premature infants
and results in a substantial health care cost burden. Several
preclinical studies indicate that A1M Pharma's candidate drug,
ROSGard™, based on the endogenous protein alpha-1-microglobulin,
restores impairments to kidney function by repairing damaged tissue
and protecting against oxidative stress. Kidney injury is a condition
which is often associated with major surgery and with cancer
treatments using radiation therapies. The company is therefore also
developing a treatment for these acute kidney injuries. The first
indication is kidney protection in connection with PRRT - a targeted
radiation therapy for cancer - with the aim of opening the
possibility of increasing treatment levels and so fight the cancer
more effectively. Every year, over 12 million people are affected by
acute kidney injuries that can lead to permanent kidney damage.

This information is information that A1M Pharma AB (publ) is obliged
to make public pursuant to the EU Market Abuse Regulation. This
information was submitted for publication through the agency of the
contact persons set out above on 9 December 2016, at 8:30 a.m CET.


Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.